Literature DB >> 15979992

Expression of interleukin-8 and monocyte chemotactic protein-1 in adenomyosis.

E Cagnur Ulukus1, Murat Ulukus, Yasemin Seval, Wenxin Zheng, Aydin Arici.   

Abstract

BACKGROUND: To clarify the inflammatory nature of adenomyosis, we aimed to investigate the expression of interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) by immunohistochemistry to determine their putative role in pathophysiology of adenomyosis.
METHODS: Adenomyosis samples, with their eutopic endometrium, were collected from 30 women undergoing hysterectomy. Endometrium from 27 women without adenomyosis were also collected as a control group. Samples were grouped according to the menstrual cycle phase and examined by immunohistochemistry for IL-8 and MCP-1.
RESULTS: In normal endometrium, secretory phase samples expressed higher levels of epithelial IL-8 than in proliferative phase samples (P = 0.01), and we observed a trend for an increased epithelial MCP-1 expression in the secretory phase samples compared with the proliferative phase samples (P = 0.07). Endometrial samples of women with adenomyosis did not show the same cyclic variation. In the secretory phase, eutopic endometrium of women with adenomyosis expressed lower levels of epithelial IL-8 and MCP-1 compared with normal endometrium (P < 0.05). The expression of epithelial IL-8 and MCP-1 was higher in the adenomyosis foci than the eutopic endometrium (P < 0.05).
CONCLUSIONS: These findings may indicate that an intrinsic abnormality of inflammatory response may be present in eutopic endometrium of women with adenomyosis, and IL-8 and MCP-1 may contribute to the pathophysiology of adenomyosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979992     DOI: 10.1093/humrep/dei154

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  L-22 enhances the invasiveness of endometrial stromal cells of adenomyosis in an autocrine manner.

Authors:  Qing Wang; Li Wang; Jun Shao; Yan Wang; Li-Ping Jin; Da-Jin Li; Ming-Qing Li
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  Blocking IL-22, a potential treatment strategy for adenomyosis by inhibiting crosstalk between vascular endothelial and endometrial stromal cells.

Authors:  Wen-Qing Shang; Jia-Jun Yu; Lei Zhu; Wen-Jie Zhou; Kai-Kai Chang; Qing Wang; Ming-Qing Li
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 3.  Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why.

Authors:  Bruce A Lessey; J Julie Kim
Journal:  Fertil Steril       Date:  2017-06-14       Impact factor: 7.329

4.  Endometrial CXCL13 expression is cycle regulated in humans and aberrantly expressed in humans and Rhesus macaques with endometriosis.

Authors:  Jason M Franasiak; Katherine A Burns; Ov Slayden; Lingwen Yuan; Marc A Fritz; Kenneth S Korach; Bruce A Lessey; Steven L Young
Journal:  Reprod Sci       Date:  2014-07-16       Impact factor: 3.060

5.  Defining the proliferative phase endometrial defect.

Authors:  Jason G Bromer; Tamir S Aldad; Hugh S Taylor
Journal:  Fertil Steril       Date:  2008-03-07       Impact factor: 7.329

6.  Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence.

Authors:  Bo Zhu; Yumei Chen; Xiaolu Shen; Xishi Liu; Sun-Wei Guo
Journal:  Reprod Biol Endocrinol       Date:  2016-10-10       Impact factor: 5.211

7.  Elevated plasma levels of lysophosphatidic acid and aberrant expression of lysophosphatidic acid receptors in adenomyosis.

Authors:  Bicheng Yang; Liqun Wang; Xiaoju Wan; Yunjun Li; Xiaohong Yu; Yunna Qin; Yong Luo; Feng Wang; Ouping Huang
Journal:  BMC Womens Health       Date:  2017-11-25       Impact factor: 2.809

8.  Activation of the cGAS-STING signaling pathway in adenomyosis patients.

Authors:  Yun Lin; Luying Wang; Mingzhu Ye; Ke-Nan Yu; Xin Sun; Min Xue; Xinliang Deng
Journal:  Immun Inflamm Dis       Date:  2021-05-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.